Notes: To study the effect of the DNA intercalating chemotherapy agent doxorubicin, the viability of HCT116 cells plated 10⁵ cell/mL were tested over a titration of doxorubicin treatment for 48 hours. Using the CellTiter 96® Aqueous Cell Non-Radioactive Cell Viability Assay, the researchers found that increasing concentrations of the drug caused increasing cytotoxicity. However, testing for caspase activation with the Caspase-Glo™ 3/7 assay revealed that apoptosis was only induced in a narrow window of these concentrations. This helped elucidate the mechanism of apoptosis induction in doxorubicin treated cells. (3214)

Notes: The Caspase-Glo^® 3/7, -8 and -9 Assays were used to  measure Caspase-3, -8, and -9 activities in mouse liver homogenates. The authors describe a modified procedure for making liver homogenates in a hypotonic extraction buffer.  Homogenates were cleared with a 15 minute spin at 13,000 x g and normalized to a 1mg/ml concentration before use the assays. Data comparing control and cSN50 peptide-treated animals at various time points are presented.  (3213)

Notes: The effects of tamoxifen and vinblastine were assayed on HepG2 and HL-60 cells using a variety of Promega’s cell-based assays. The CellTiter-Glo^® Luminescent Cell Viability Assay, CellTiter 96^® AQueous One Solution Cell Proliferation Assay, and CellTiter-Blue^® Cell Viability Assay were used to test the effects of 0-100µM tamoxifen on HepG2 cell viability after an incubation period ranging from 0-24 hours. Cell membrane integrity was assessed with the CytoTox-ONE™ Homogeneous Membrane Integrity Assay. The Caspase-Glo^® 3/7 Assay was also used to measure Caspase 3/7 activity after 0-100µM tamoxifen treatment. (3189)